Value Chain Analysis of the Private Health in Brazil.

Commercial Relationships

The private health industry in Brazil operates through a complex web of commercial relationships connecting various players across its value chain. These relationships are fundamental to the functioning of the sector, facilitating the flow of products, services, and financial resources. Understanding these interactions is crucial to grasping the dynamics of the Brazilian private health market.

At the foundational stage of Research and Education, while direct commercial relationships within the private sector for fundamental research might be less visible in the provided context, private universities and training institutions engage in a direct commercial relationship with students and healthcare professionals. Students pay tuition fees for undergraduate and postgraduate programs, while professionals pay for continuing education courses and certifications. These institutions, in turn, may have commercial relationships with medical associations and societies for program accreditation and dissemination. The R&D divisions of pharmaceutical and medical device companies primarily operate through internal investments and may engage in commercial partnerships with private research centers for specific studies or clinical trials, often involving contractual agreements for funding, data sharing, and intellectual property rights.

In the Supply of Health Products and Technology step, the primary commercial relationships involve manufacturers (pharmaceutical companies, medical device companies, and hospital supply producers) and distributors. Manufacturers sell their products in bulk to wholesale distributors through supply agreements. These agreements detail pricing, volumes, delivery schedules, and payment terms. Multinational corporations often operate through local subsidiaries or appointed distributors in Brazil. Local manufacturers also engage in direct sales or utilize the same distribution channels. Biotechnology companies may license technologies or products to larger pharmaceutical or medical device companies, involving complex royalty and milestone payment structures. The pharmaceutical industry's sales to pharmacies can be direct or through wholesale distributors, with commercial terms varying based on volume, payment terms, and promotional agreements.

The Distribution step involves the movement of goods from manufacturers to healthcare providers and, in the case of retail pharmacies, directly to consumers. Pharmaceutical wholesalers purchase from manufacturers and sell to pharmacies (both chains and independent) and healthcare institutions. These relationships are governed by supply contracts and logistics agreements. Pharmacy chains often have centralized purchasing agreements with manufacturers or large distributors to leverage their buying power. Independent pharmacies may rely more on wholesalers for their stock. Medical device distributors have commercial relationships with manufacturers (often exclusive distribution agreements) and sell or lease equipment to hospitals, clinics, and laboratories. This can involve complex sales contracts, maintenance agreements, and technical support service contracts. Specialized healthcare logistics providers contract with manufacturers and distributors to handle the specific transportation and storage needs of health products, ensuring compliance with regulatory requirements.

Financial Intermediation is a central hub of commercial relationships in the private health value chain. Health plan operators and health insurance companies have a primary commercial relationship with beneficiaries (individuals or, more commonly, corporate groups) through the sale of health plans and insurance policies. This involves collecting monthly premiums or contributions in exchange for access to a defined network of healthcare providers or reimbursement for services. Administradoras de Benefícios act as intermediaries, contracting group health plans with operators on behalf of affiliated legal entities (like professional associations or unions) and managing the relationship with the beneficiaries of these groups, receiving fees for these administrative services. Health plan operators and insurance companies, in turn, establish commercial relationships with healthcare service providers (hospitals, clinics, laboratories, etc.) through accreditation agreements. These contracts define the scope of services covered, payment models (e.g., fee-for-service, capitation, bundled payments), authorization processes, and quality metrics. Unimed cooperatives have a unique structure where the physicians are both owners and service providers, creating an internal commercial dynamic related to service provision and cooperative dividends.

In the Healthcare Services step, the direct commercial relationship is between the healthcare provider (hospitals, clinics, laboratories, etc.) and either the patient (for out-of-pocket services) or, more commonly in the private system, the financial intermediary (health plan operator or insurance company). When a patient with a health plan receives care, the provider bills the health plan operator based on the agreed-upon terms in their accreditation contract. For patients paying out-of-pocket, the relationship is a direct fee-for-service transaction. Hospitals may also have commercial relationships with staffing agencies for medical professionals or with other specialized service providers (e.g., laundry, food services). Diagnostic services providers (laboratories and imaging centers) have commercial relationships with referring physicians and clinics, although the billing and payment are typically handled through the health plan operators for insured patients.

Finally, Complimentary Health Services providers (dentists, psychologists, nutritionists, home care agencies, etc.) also have commercial relationships with patients (direct payment) or with health plan operators (through accreditation, especially for dental plans, or specific service agreements). Operators of exclusively dental plans have a similar structure to medical plan operators, contracting with beneficiaries and accrediting dental service providers.

An important overarching relationship, although not strictly commercial in the traditional sense of buying and selling, exists between the private health sector players and the Regulation bodies, primarily ANS and ANVISA. Players must comply with regulations, pay fees for licenses and registrations, and are subject to fines and penalties for non-compliance. While not a direct commercial exchange for services rendered, this regulatory relationship imposes significant financial and operational considerations on all players in the value chain.

Products and Services Exchanged

The value chain of the private health industry in Brazil involves the exchange of a wide array of products and services, moving from upstream supply to direct patient care and financial management.

In the Research and Education phase, the primary "products" exchanged are knowledge, skills, and qualified personnel. Research institutions and R&D divisions produce research findings, patents, and new medical technologies or protocols. Educational institutions provide academic programs, diplomas, and professional certifications to students. Continuing education providers offer specialized courses, workshops, and access to updated medical knowledge for professionals. These are exchanged for funding, tuition fees, and professional development fees.

The Supply of Health Products and Technology step involves the exchange of tangible goods. The Pharmaceutical Industry supplies medicines, vaccines, and other pharmaceutical products. The Medical Devices Industry provides a vast range of equipment, instruments, implants, and diagnostic technologies, from simple consumables like syringes and gloves to complex MRI machines and surgical robots. The Hospital and Clinical Supplies segment exchanges consumables, materials, and general supplies necessary for the daily operation of healthcare facilities. These products are exchanged for monetary payment, typically through purchase orders and invoices along the distribution chain.

In the Distribution step, the core service exchanged is logistics and delivery. Pharmaceutical distributors exchange the service of warehousing, inventory management, and transportation of medicines for payment from pharmacies and healthcare providers. Medical device distributors provide the service of delivering, installing, and often maintaining complex equipment, exchanged for payment from hospitals and clinics. Distributors of hospital and clinical supplies exchange the service of reliable and timely delivery of a wide variety of consumables for payment from healthcare facilities. Retail pharmacies, in addition to selling medicines, also provide basic health services like measurement of blood pressure and temperature, and guidance on medication use, exchanged for direct payment from consumers.

Financial Intermediation primarily exchanges financial protection and access to healthcare services. Health plan operators and insurance companies exchange health plans and policies, which represent a promise of access to a network of accredited providers or reimbursement for covered medical expenses, for periodic premium payments from beneficiaries. Within their relationships with providers, health plan operators exchange the service of patient referral and payment processing for healthcare services rendered by the providers to their beneficiaries. Administradoras de Benefícios exchange administrative and management services for group health plans for fees from the affiliated legal entities and potentially from the health plan operators.

The Healthcare Services step is where direct patient care is delivered. Hospitals provide inpatient medical and surgical care, intensive care, emergency services, and diagnostic procedures. Clinics offer outpatient consultations, basic diagnostic tests, vaccinations, and minor procedures. Diagnostic services providers (laboratories and imaging centers) exchange the service of performing clinical tests and imaging examinations, interpreting results, and issuing reports for payment, usually from health plan operators or directly from patients. Ambulatory care centers provide a range of outpatient medical and surgical services. Therapy and rehabilitation centers exchange specialized therapeutic interventions for payment. These services are exchanged for payment based on fee schedules, per diem rates, capitation, or other contractual arrangements.

Complimentary Health Services involve the exchange of specialized health and wellness services. Dental clinics provide preventive and restorative dental treatments. Wellness programs offer health assessments, coaching, and educational services. Home care agencies provide medical, nursing, and support services in patients' homes. Mental health professionals offer psychological and psychiatric consultations and therapy. Nutritionists provide dietary assessments and personalized meal plans. These services are exchanged for direct payment from patients or payment through accredited health plans (particularly for dental and some therapy services).

Throughout the value chain, there is also an implicit exchange of information, including patient data (while adhering to privacy regulations), treatment protocols, billing information, and regulatory updates, which is essential for coordinated care and compliance.

Business Models

Various business models are employed across the private health value chain in Brazil, reflecting the diverse nature of the activities and players involved.

In Research and Education, private universities and training centers primarily operate on a tuition-based model, where revenue is generated from student fees. They may also seek grants and funding for research activities. R&D divisions within companies are cost centers funded by the parent company's revenue from product sales. Partnerships with research centers might involve fee-for-service models for specific research tasks or collaborative models with shared funding and potential revenue sharing from resulting intellectual property.

The Supply of Health Products and Technology largely follows traditional manufacturing and sales models. Pharmaceutical and medical device companies operate on a product sales model, manufacturing goods and selling them through distribution channels. Their revenue comes from the price of the products sold. Biotechnology companies may utilize a licensing model, generating revenue by allowing other companies to use their technology or products in exchange for fees or royalties.

Distribution businesses primarily use a wholesale or retail margin model. Wholesalers buy products in bulk at a lower price from manufacturers and sell them at a slightly higher price to pharmacies and providers, earning a margin on each transaction. Pharmacy chains and independent pharmacies operate a retail model, selling directly to consumers at a markup from their purchase cost. They may also generate revenue from providing basic health services. Medical device distributors use a sales or leasing model for equipment, often including long-term maintenance contracts as a recurring revenue stream. Specialized logistics providers use a service fee model, charging for transportation, warehousing, and handling based on volume, distance, and service level.

Financial Intermediation is dominated by the insurance and prepaid health plan models. Health plan operators and insurance companies primarily use a premium-based model, collecting regular payments from beneficiaries (or their employers) in exchange for covering healthcare costs within defined limits. Risk assessment and actuarial calculations are central to this model to ensure financial sustainability. Within this, different sub-models exist, such as:

• Accredited Network Model: The operator contracts with a network of independent providers and pays them for services rendered to beneficiaries based on agreed fee schedules (fee-for-service is common, though there's a push for alternative models).
• Verticalized Model: Operators own and operate their own hospitals, clinics, and diagnostic centers, providing services to their beneficiaries within their proprietary network. This model aims to control costs and integrate care. Hapvida NotreDame Intermédica is a prominent example of this model.
• Reimbursement Model: Beneficiaries can choose any provider and are reimbursed a percentage of the cost by the insurer, up to a plan-defined limit. This is more common in higher-end plans.
• Administradoras de Benefícios Model: These entities operate on a service fee model, charging for the administration and management of group health plans.

Healthcare Services providers employ various business models depending on their type and ownership. Hospitals operate complex service delivery models, generating revenue from procedures, daily room rates, use of facilities, and ancillary services. They are typically paid by health plan operators or directly by patients. Private clinics and individual practitioners primarily use a fee-for-service model, charging for consultations, procedures, and other services. Diagnostic services providers also use a fee-for-service model for tests and imaging, billing health plans or patients. Ambulatory care centers and therapy/rehabilitation centers also operate on service fee structures. Philanthropic hospitals, while part of the private sector, may rely on donations and government support in addition to payments for services.

Complimentary Health Services providers use business models similar to other healthcare service providers, primarily fee-for-service. Dental clinics charge for procedures. Home care agencies charge based on the type and duration of care provided. Mental health professionals and nutritionists charge for consultations and therapy sessions. Operators of exclusively dental plans use a premium-based model like medical plan operators, but focused solely on dental coverage.

Across the value chain, there's a growing interest in alternative payment models beyond traditional fee-for-service, such as capitation (fixed payment per patient), bundled payments (single payment for an episode of care), and value-based care models (tying payment to health outcomes) to control costs and improve quality, though adoption is still in early stages for many relationships. Public-Private Partnerships (PPPs) represent another business model where private entities contract with the government to manage or provide services in public health facilities, although this blurs the lines with the public sector.

Bottlenecks and Challenges

Despite its significant size and importance, the private health industry in Brazil faces several substantial bottlenecks and challenges across its value chain in 2024 and 2025.

A major challenge lies in the financial sustainability of the system. Rising healthcare costs, driven by factors such as technological advancements, increasing utilization of services, and inflation, put pressure on both health plan operators and beneficiaries. Operators face the challenge of balancing affordable premiums with the need to cover increasing medical expenses, leading to significant premium adjustments, particularly for individual plans. Beneficiaries, in turn, face the challenge of affording these rising costs, potentially leading to decreased access to private healthcare or migration to less comprehensive plans.

The relationship between financial intermediaries (health plan operators) and healthcare service providers is a significant source of tension and bottlenecks in provider payment and accreditation. Providers often complain about low reimbursement rates from health plans and delays in payment processing. This can impact the financial viability of hospitals, clinics, and laboratories and affect their ability to invest in infrastructure and technology. The accreditation process itself can be bureaucratic and challenging for providers. The push towards alternative payment models by operators is also a challenge for providers who are accustomed to fee-for-service.

Regulatory challenges pose significant bottlenecks. ANS, the regulatory body for supplementary health, faces challenges in keeping pace with the evolving market, including the emergence of new business models like health discount cards, which operate in a less defined regulatory space. A critical and current challenge for ANVISA, which regulates health products, is a significant staffing shortage due to retirements, potentially creating bottlenecks in product approvals, inspections, and border control, impacting the timely availability of essential medicines and medical devices. The complexity and sometimes conflicting nature of regulations from different bodies (ANS, ANVISA, Ministério da Saúde) can also create compliance burdens for players.

Access to and quality of healthcare services remain challenges despite the existence of a large private sector. While private plans offer an alternative to the public SUS, beneficiaries still face bottlenecks in accessing specialized care and certain high-cost procedures, sometimes experiencing long wait times or difficulties finding accredited providers in specific locations. Regional disparities exist in the availability and quality of private healthcare infrastructure and professionals. Market concentration in certain regions can also lead to reduced service quality and increased user complaints.

The supply chain for health products can also experience bottlenecks. Relying on imports for a significant portion of medical devices and some pharmaceuticals exposes the system to global supply chain disruptions and currency fluctuations. Regulatory hurdles related to the importation and registration of new products by ANVISA can also cause delays in bringing innovative treatments and technologies to the Brazilian market.

Finally, the interconnectedness and dual use of the public (SUS) and private systems present a complex challenge. While the private sector complements SUS, there are debates about the allocation of public resources that may indirectly benefit the private sector (e.g., tax exemptions for health plan expenses) while SUS faces underfunding. This dynamic, coupled with the reality of many Brazilians using both systems, creates complexities in planning, resource allocation, and ensuring equitable access to care.

References

• ABRE. Setor farmacêutico pode crescer quase 10% em 2024, aponta pesquisa. (2024, August 12).
• A Gazeta. Confira os laboratórios de análises clínicas vencedores da pesquisa. (2020, August 14).
• Abradilan. As 15 maiores indústrias farmacêuticas. (2023, November 27).
• Abradilan. Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas e impacto no bolso do consumidor. (2025, April 28).
• Agência Gov. Março de 2024: planos de assistência médica somam mais de 51 milhões de usuários. (2024, May 6).
• Agência Nacional de Saúde Suplementar (ANS). ANS divulga dados de beneficiários em novembro de 2024. Portal Gov.br. (2025, January 3).
• BenefíciosRH. 9 Maiores Operadoras de Planos de Saúde para 2025. (2024, May 23).
• CDPI Pharma. Brasil tem 18 Indústrias Farmacêuticas Bilionárias.
• CNseg. Planos de saúde alcançam 51 milhões de beneficiários em janeiro de 2024. (2024, March 14).
• FenaSaúde. O que é Saúde Suplementar? | CNseg.
• GIFE. Saúde Privada no Brasil: estudo inédito do IEPS e Umane analisa setor e suas relações com o SUS nas últimas décadas. (2024, October 28).
• HSM Management. Healthcare: O desafio é alinhar a cadeia de valor.
• INAFF. Confira o ranking das maiores indústrias farmacêuticas em 2024. (2025, January 13).
• ISTOÉ DINHEIRO. Planos de saúde ganham mais de 860 mil clientes em 2024 e atingem recorde de beneficiários. (2025, February 5).
• Investe SP. Brasil soma 47% do mercado farmacêutico na América Latina. (2024, May 17).
• Joov. Lista de melhores planos de saúde em 2024. (2024, October 25).
• Labtest Diagnóstica. Gestão Laboratorial: criando a estratégia para 2024. (2023, December 18).
• Medicina SA. O mercado de saúde no Brasil: desafios e potencial de crescimento. (2024, November 28).
• Medi Corretora. Melhores planos de saúde 2024: Confira aqui! (2024, October 7).
• Medlife Blog. 5 melhores laboratórios Distrito Federal.
• Mordor Intelligence. Mercado de dispositivos médicos- Tamanho, relatório- Visão geral e compartilhamento do setor.
• Mordor Intelligence. Mercado de Diagnóstico Clínico- Tamanho, visão geral e tendências do setor.
• Mordor Intelligence. Tamanho do mercado de serviços de laboratório clínico, tendências e participação da indústria.
• Mordor Intelligence. Tamanho do mercado Dispositivos médicos portáteis e análise de participação - Relatório de Pesquisa da Indústria - Tendências de Crescimento.
• Moody's Local. Setor de Saúde no Brasil: Estrutura, Fundamentos e Tendências. (2025, January 30).
• NSC Total. O mercado de healthcare no Brasil. (2019, June 21).
• Planalto. Lei nº 9.656, de 3 de junho de 1998.
• Poder360. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bi em 2024. (2025, March 9).
• Previva. Quais são as modalidades de operadoras de planos de saúde no Brasil? (2024, July 1).
• Pride Consultoria. Melhores planos de saúde em 2024: Saiba quais são!
• ResearchGate. Cadeia de valor da saúde: um modelo para o sistema de saúde brasileiro. (2021, January 4).
• Saúde Business. Setor de saúde registra crescimento anual de 5,3% no mercado de trabalho. (2024, March 22).
• Sebrae. Painel Setorial Saúde.
• Trier Sistemas. Vendas do varejo farmacêutico atingem R$ 158,4 bilhões em 2024. (2025, March 6).
• Unilab. Como os melhores laboratórios do Brasil funcionam?
• USP Congresso. preços e níveis de complexidade dos serviços praticados por hospitais privados junto à operadoras de.
• VEJA. Exportações de dispositivos médicos ultrapassam US$ 1 bilhão em 2024. (2025, February 17).